



Version: [25 March 2026]

Country: United Kingdom

Outlook Therapeutics Inc: Methodological note for HCP/ORDM/HCO disclosure 2025

Data year: 2025

Year of publication: 2026

This disclosure has been prepared in accordance with the 2025 ABPI Code of Practice. It details Transfers of Value (ToVs) made by Outlook Therapeutics Inc to healthcare professionals (HCPs), healthcare organisations (HCOs), and other relevant decision makers (ORDMs) in the UK.

This report includes all relevant ToVs made directly or indirectly in connection with the development and sale of prescription-only medicines for human use.

Contents

1	Definitions	2
1.1	Recipients.....	2
1.2	Kind of ToVs	2
2	Disclosure's Scope	3
2.1	Products concerned	3
2.2	Company concerned	3
2.3	Excluded ToVs.....	3
2.4	ToVs date.....	3
2.5	Direct ToVs	3
2.6	Indirect ToVs.....	3
2.7	Non-monetary ToVs.....	3
2.8	ToVs in case of partial attendances or cancellation and refund	3
2.9	Cross-border activities.....	3
2.10	R&D	3
2.11	Voluntary disclosure	3
3	Specific considerations	4

3.1	Country unique identifier	4
3.2	Self-incorporated HCP.....	4
3.3	Multi-year agreements.....	4
3.4	Country specificities.....	4
3.5	Quality Checks	4
4	Data protection legal basis	4
4.1	Consent collection	4
4.2	Legitimate interests	4
5	Form of disclosure	4
5.1	Date of publication.....	4
5.2	Disclosure platform.....	4
5.3	Disclosure language.....	5
6	Disclosure financial data	5
6.1	Currency	5
6.2	VAT included or excluded	5
6.3	Calculation rules.....	5
7	Additional Information	5

1 Definitions

1.1 Recipients

Health Professionals (HCPs): Defined as per the ABPI Code as individuals who may prescribe, purchase, supply, recommend, or administer medicinal products. Outlook Therapeutics did not make any transfers of value (ToVs) to any retired HCPs. It did however make a ToV to an HCP who was located in the United Kingdom at the time of the ToV but has since re-located internationally.

Other Relevant Decision Makers (ORDMs): Outlook Therapeutics did not make any ToVs to NHS personnel who can influence the prescription or purchase of medicines that were not HCPs.

Healthcare Organisations (HCOs): Legal entities such as healthcare providers, hospitals, clinics, universities, and learned societies.

1.2 Kind of ToVs

ToVs are disclosed under the following categories: -

Contribution to Costs of Events: Includes registration fees, travel, subsistence and accommodation.

Fees for Service and Consultancy: Payments for services such as speaking engagements or advisory boards.

Related Expenses.

2 Disclosure's Scope

2.1 Products concerned

Disclosures relate to prescription only medicines.

2.2 Company concerned

This disclosure covers Outlook Therapeutics Inc. It includes ToVs made to UK-based HCPs/HCOs.

2.3 Excluded ToVs

We have excluded items of low value (e.g., pens/pads, where permitted), meals/hospitality (which are capped but not reportable under Disclosure UK), and ordinary course commercial purchases.

2.4 ToVs date

We use the Payment Date (the date the money left our account) rather than the activity date to determine the reporting year.

2.5 Direct ToVs

[ToVs made directly from our company to the recipient's bank account.

2.6 Indirect ToVs

ToVs made through third-party agencies (e.g., event organisers). We track these to the end-recipient HCP/HCO.

2.7 Non-monetary ToVs

Benefits in kind (e.g., flights booked by the company) are disclosed based on the actual cost incurred by the company.

2.8 ToVs in case of partial attendances or cancellation and refund

We report the actual cost incurred by Outlook Therapeutics. If an HCP cancels and the company either receives a refund or is not required to make payment, no ToV is reported. If a full or partial cancellation fee is paid to the HCP, it is reported under "Fees for Service".

2.9 Cross-border activities

All ToVs in this report have been made by a non-UK based company to a UK HCP. They have been captured in our global transparency system and included in this UK report.

2.10 R&D

We have not made any R&D ToVs related to the planning or conduct of non-clinical studies, clinical trials, and non-interventional studies during 2025.

2.11 Voluntary disclosure

Our disclosures do not go beyond what is required by the ABPI.

3 Specific considerations

3.1 Country unique identifier

[Through a process of internal code allocation and specific in house financial codes, a detailed data download is performed for all payments made to HCP's, ORDM's and HCO's during the calendar year.]

3.2 Self-incorporated HCP

[ToVs to a company owned by a single HCP are treated as ToVs to that individual HCP.]

3.3 Multi-year agreements

For contracts spanning multiple years, ToVs are disclosed in the year the specific payment instalment was made.

3.4 Country specificities

Outlook Therapeutics was not involved in any collaborative working projects during 2025.

3.5 Quality Checks

We perform a three-way match between our internal records (including our CRM system), finance system, and third-party agency reports before final submission.

4 Data protection legal basis

4.1 Consent collection

For each activity, consent is requested as part of the contract for an HCP agreeing to provide services for the organisation. This contract is stored electronically on a password protected network to ensure data protection is maintained whilst allowing review of records if required in future.

In 2025 there were no transfers of value to recipients who had not provided their consent to disclose as part of their contractual agreement with Outlook Therapeutics. Should this be the case in the future, all transfers of value without consent to disclose will be included in the aggregate value for the organisation.

Should an HCP provide consent for one meeting but decline consent for another, all interactions will be included in the aggregate value. No partial disclosures will be made.

4.2 Legitimate interests

N/A

5 Form of disclosure

5.1 Date of publication

Data is submitted by March 31, 2026, for publication by June 30, 2026

5.2 Disclosure platform

Data is published on the central Disclosure UK platform.

5.3 Disclosure language

English

6 Disclosure financial data

6.1 Currency

All values are reported in GBP (£). Foreign currency is converted using the exchange rate on the date of the transaction.

6.2 VAT included or excluded

All figures are reported as gross and are therefore inclusive of VAT where VAT has been charged.

6.3 Calculation rules

Exact costs for ToVs were ascertainable for the majority of costs. Where multiple attendees were provided sustenance as part of a contribution to attendance of an event the total cost was divided by the number of attendees.

7 Additional Information

N/A.